Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- AnGes Bags Conditional Approval for Collategene Gene Therapy
March 27, 2019
- Fujifilm, NCC Join Hands for I/O Research, Combining Liposomes with Immune Checkpoint Inhibitors
March 27, 2019
- Boehringer’s Ofev Gets Orphan Status for ILD in Systemic Sclerosis
March 27, 2019
- Novartis Snags Japan Approval for CAR-T Therapy Kymriah
March 26, 2019
- Novartis to Tap Disease Registry for Kymriah’s All-Case PMS: Exec
March 26, 2019
- SanBio to Move Ahead with SB623 Development in Stroke after PII Miss: President
March 26, 2019
- Avanir’s Alzheimer’s Agitation Drug Hits Primary Goal in PIII
March 26, 2019
- AstraZeneca Grabs All Global Fasenra Rights in Expanded Pact with Kyowa Kirin
March 26, 2019
- Vimpat IV Version Hits Japan Market: UCB, Daiichi Sankyo
March 26, 2019
- Ono Chief Recounts Long and Winding Road of Opdivo Development, Thanks Kyoto Univ. Professor
March 25, 2019
- JCR Files Temcell for Epidermolysis Bullosa
March 25, 2019
- Japan Biosimilar Market Could Grow Like in Europe If Incentives Improved: Sandoz Japan Chief
March 25, 2019
- Eisai Going Ahead with Global PIII for BAN2401 despite Aducanumab Setback
March 25, 2019
- Analyst Says Drug Makers Can’t Recoup Investment in Overcompetitive Oncology Arena
March 22, 2019
- Biogen/Eisai’s Aducanumab Fails, Dashing Hopes in Alzheimer’s Field
March 22, 2019
- J-TEC Submits Japan’s First Regenerative Medicine Product in Ophthalmology Field
March 22, 2019
- Mitsubishi Tanabe Sets Up Sales Subsidiary in Malaysia for Independent Marketing
March 22, 2019
- Takeda Taps Neuro-Psychiatric Expert Kajii as T-CiRA Chief
March 22, 2019
- Nippon Shinyaku Licenses Dravet Syndrome Treatment from Zogenix
March 22, 2019
- Chugai, SRL Link Up for Cancer Gene Mutation Tests
March 22, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…